Lysine l ‐Lactylation: Bridging Metabolism, Chromatin and Disease
Cell Proliferation · 2026-08 · 59 (8)
DOI: 10.1111/cpr.70262 ↗At a glance
Übersichtsarbeit in Cell Proliferation, published online on 2026-07-12. Written by Anoosha Malik and 10 co-authors. Institution: Department of Biopharmaceutics, Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Di…. Major MEDLINE topics: Protein Processing, Post-Translational, Chromatin, Lysine. Cited 2 times so far (Crossref); 240 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Fundamental Research Funds of Zhejiang Sci-Tech University.
Abstract (original language)
Lysine L‐lactylation (K L‐la ) is a newly identified metabolite‐derived post‐translational modification that directly bridges cellular metabolic states to chromatin regulation and protein function. Mounting evidence shows that K L‐la has pivotal roles in transcription regulation and diverse cellular processes and is implicated in multiple pathophysiological conditions. This review comprehensively examines K L‐la across both histone and non‐histone substrates in biology and disease. We first illustrate the historical development of K L‐la and distinguish it from its isomers. We then delineate the enzymes regulating K L‐la , examine its crosstalk with other PTMs, and discuss its roles in cell signalling and other biological processes. Particular emphasis is placed on mechanisms through which K L‐la contributes to various human diseases such as cancer, viral infections, neurodegenerative disorders, cardiovascular conditions, metabolic abnormalities and immune dysregulation. Finally, we provide an in‐depth analysis of emerging therapeutic strategies targeting K L‐la and highlight future directions for translating mechanistic insights into clinical applications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biopharmaceutics, Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Science and Medicine, Zhejiang Sci-Tech Univer…
- Department of Orthopaedics, The 903rd Hospital of the Joint Logistic Support Force, Hangzhou, China.
- Department of Orthopaedic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Clinical Laboratory, Zhejiang Rehabilitation Medical Center, Hangzhou, Zhejiang, China.
- Clinical Laboratory, The Second Hospital of Jiaxing, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
ORCID profiles: Guiqian Chen
Funding
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
- Fundamental Research Funds of Zhejiang Sci-Tech University
Cite
APA
Malik, A., Dilawar, M., Liao, J., Zheng, J., Qian, Q., Xu, M., Lin, S., Zhu, X., Ge, Q., Jin, L., & Chen, G. (2026). Lysine l ‐Lactylation: Bridging Metabolism, Chromatin and Disease. Cell Proliferation, 59(8). https://doi.org/10.1111/cpr.70262
Vancouver
Malik A, Dilawar M, Liao J, Zheng J, Qian Q, Xu M, et al. Lysine l ‐Lactylation: Bridging Metabolism, Chromatin and Disease. Cell Proliferation. 2026;59(8). doi:10.1111/cpr.70262
BibTeX
@article{Malik2026,
author = {Malik, Anoosha and Dilawar, Muhammad and Liao, Junguang and Zheng, Jie and Qian, Qitao and Xu, Ming and Lin, Sisi and Zhu, Xiaobo and Ge, Qiuwei and Jin, Limin and Chen, Guiqian},
title = {Lysine l ‐Lactylation: Bridging Metabolism, Chromatin and Disease},
journal = {Cell Proliferation},
year = {2026},
volume = {59},
number = {8},
doi = {10.1111/cpr.70262}
}
EUVIMED